vesicles are released during cell undergoing apoptosis ranged from 50 to 2000 nm, respectively. [7] [8] [9] Extracellular vesicles serve as an appealing source for the development of biomarkers as their membrane-bound structure to protect against exogenous proteases and RNases. 10, 11 The biological function of EVs is performed by cytosolic lipids, proteins, DNA, mRNA, miRNA, lincRNA and other non-coding RNAs, as well as cell membrane. 12 In addition, cancer cell releases more EVs than that normal one does. 13 Herein, we introduce EVs briefly and provide a comprehensive overview of their biophysical properties, roles and applications in the most common urologic neoplasms, including kidney, prostate and bladder, and discuss potential clinical applications in the future.
| E V CL A SS E S , B I OG ENE S IS AND CONTENTS
Our current understanding of EVs indicates that at least four heterogeneous types of EVs have been identified based on their mechanism of formation and distinguished size: microvesicles, exosomes, oncosomes or large oncosomes, and apoptotic bodies ( Table 1 ). In general, the formation of exosomes and microvesicles is two completely different approaches, but they function similarly. Oncosomes or large oncosomes resemble the way of microvesicles via membrane budding. Apoptotic bodies specifically arise resulting in indiscriminate membrane bubbling during apoptosis (Figure 1 ).
Exosomes generally form an early endosome by the endocytosis and internalization of cell-surface receptors into membrane-bound vacuoles in the first step, 14 which then matures to generate a late endosome within undergoing several changes, such as the limiting membrane of the late endosome then buds inward and pinches off as the result of the formation of intraluminal vesicles (ILVs), also known as multivesicular bodies, and ILVs traffick to and fuse with the plasma membrane leading in releasing exosomes eventually. 15 ESCRT-0-III plays significant roles in driving exosome formation 16,17 ; in addition, multivesicular bodies could intermediate in the lysosomal degradation pathway. 18 However, the mechanisms related to the fusion of multivesicular bodies with the cellular membrane are uncovered, which may be regulated by several factors including lipid ceramide and Rab GTPase (including Rab5 and Rab7) proteins and ESCRT. [19] [20] [21] Numerous literatures have indicated that several biomarkers expressed in the exosome differentially compared with another types of EVs, including heat shock proteins (eg HSP60, 70 and 90), tetraspanins (eg CD9, CD63 and CD81), membrane transporters, fusion proteins, ALG-2-interacting protein X (Alix) and tumour susceptibility gene 101 protein (TSG101). 20, 22 In contrast, microvesicles with nano-sized with 100-1500 nm are straightforwardly shed from the cellular membrane responding to stimuli or physiological conditions. 23 factor 6 (ARF6) can meditate the freeing of protease-loaded vesicles from the cellular membrane due to the crosstalk with Rho signalling pathways. [24] [25] [26] Moreover, microvesicles are specifically produced in the cellular membrane regions that are linked to be enriched in cholesterol, ceramide and lipid rafts. 27 TSG101 is also known to interact with accessory proteins Alix and arresting domain-containing protein-1 (ARRDC1) during releasing microvesicles, illustrating that microvesicles sharing some same characteristics with exosomal biogenesis. 28 As described for microvesicles, oncosomes and large oncosomes are generated by plasma membrane budding, with amoeboid-like phenotype. Notably, oncosomes and large oncosomes specially derived from cancerous cells are indicated to play vital roles in malignancies invasion. The term "oncosome" is firstly referred that the EVs with size range from 100 to 500 nm. Subsequently, large non-apoptotic EVs were detected in prostate tumours with their unusual size in 1-10 mm, called large oncosomes. Currently, some studies demonstrate that oncosomes and large oncosomes are definitely different variety of EVs respecting to their size, cargo contents and target effects, and additional studies are therefore of the essence to clarify differences between oncosomes and large oncosomes.
Apoptotic bodies, imposing an effect on the cellular response by transmitting their substance towards receptor cells, are generated during undergoing programmed cell death with 500-4000 nm, and their content contains fragmented cytoplasmic organelles as well as destructive nuclei. 29, 30 
| ISOL ATI ON TECHNI QUE S OF E VS
No remarkable consensus is in existence of the best approach for isolation, qualitative and quantitative analysis of EVs. There are listing several methods for the isolation of EVs ( Figure 2 ) and demonstrate the available disadvantages and advantages as well ( Table 2 ). 31
| CENTRIFUG ATI ON
In recent, differential centrifugation is the most common technique in responding to isolating EVs, and this approach is consisting of three main centrifugation processes: low speed to eliminate a main portion of the cells, then intermediate speed to subside cell debris and aggregate biopolymers and the other structures with density higher than that of EVs and finally high speed to pellet extracellular vesicles. The advent of density gradient ultracentrifugation increases the efficiency of particle separation according to their buoyant density.
However, an important disadvantage of differential centrifugation cannot thoroughly separate protein and other non-exosomal particles from EVs, limiting its efficacy and usage in clinical studies for diagnosis, to large extent, the advent of density gradient ultracentrifugation that reverses the poor separation efficiency due to their buoyant density, and it is frequently used for EV isolation though with a considerable loss of EVs. 31, 32 F I G U R E 1 Release and uptake mechanisms of extracellular vesicles. Extracellular vesicles can be classed as exosomes, microvesicles and apoptotic bodies, based on the mechanism by which they are released from cells and differentiated based on their size and content. MVs, and oncosomes or large oncosomes are directly shed or bud from the plasma membrane. Apoptotic bodies are released from the cell undergoing programmed cell death. Exosomes are formed by inward budding of multivesicular bodies
| FILTR ATI ON
Due to the micropores or nanopores, EVs can also be isolated by numerous protocols (eg ultrafiltration and hydrostatic dialysis).
Ultrafiltration is currently available method used for EV isolation, which represents an efficient alternative to ultracentrifugation. It involves the use of membrane filters with a narrow range of pore size distribution to deplete the proteins with molecular weight over 100 kDa, cell debris and floating cells. However, the size of filters is especially suitable for cell culture media and urine samples, which
The common methods to isolate EVs. Straight brackets: isolated EVs; yellow: soluble components; and blue: buffer. A, In differential centrifugation, separation is based on sedimentation velocity, largely depended by size; B, in density gradient centrifugation, separation is relied on buoyant and density; C, size exclusion chromatography uses a porous matrix (dotted circles) that separates on size; D, in ultrafiltration, separation is based on size; E, in immunocapture assays, EVs are captured based on the presence of specific EVs surface molecules. F, in precipitation, EVs isolation via adding some water-excluding polymers to sample to force the precipitation of small EVs out. G, In microfluidic device, EVs isolation via combining several methods such as immunoaffinity and filtration systems. Copyright 2017, University of Helsinki, Frank AW Coumans 31
TA B L E 2 Summary of EVs isolation techniques

Methods
Isolation method
Isolation Principle
Advantages
Limitations
Centrifugation Differential centrifugation limit their applications to clinical routine tests. Hydrostatic filtration dialysis (HFD), another approach developed for isolating EVs from urine samples, shows its advantages on the removal of ultracentrifugation via multiple steps and the possibility of isolating EVs from highly diluted solutions. Gel filtration, also called size exclusion chromatography, is one of the methods to collect EVs based on the basis of the size differences, and the disadvantages of this method are its low yield and rather expensive chromatographic sorbent. 33, 34 
| PRECIPITATI ON ME THODS
The current research provides numerous protocols for EV isolation via adding some water-excluding polymers to sample, and subsequently force the precipitation of small EVs out, its time-saving and easy usage make it suitable for clinical use, though show unavoidable contamination of the isolated EVs with proteins, protein complexes, lipoproteins and nucleoproteins, as well as viral and other particles. 35, 36 There are several polymer kits available that have already applied for purifying the EVs, such as hydrophilic polymers, protamine, sodium acetate and proteins with organic solvent (PROSPR) with along their disadvantages and advantages demonstrating in Table 2 .
| IMMUNOAFFINIT Y ISOL ATION ME THODS
Immunoaffinity isolation is another approach to isolate the EVs with increasing purity, owing to selectively exploiting the presence of specific molecules in the small EV surface 37 ; for example, the lipids, proteins and polysaccharides are common substances that exposed on the surface of EVs, as a result, showing potency in being ligands for manifold molecules. Generally, there are five main methods for the isolation of EVs based on immunoaffinity, including antibodies to EV receptors, 38 phosphatidylserine-binding proteins, 39 heparinmodified sorbents 40 and binding of heat shock proteins, 34 as well as lectins. 41 Although along with evident advantages of the EV purified isolation, the expensive costs, and the insufficient efficiency of isolation, and difficulties encountering in the process of isolation the large volumes of EVs, which substantially limits the applicability of immunoaffinity isolation methods.
| MICROFLUIDIC DE VICE S
Microfluidic devices are composed of a network of microchannels with different sizes, which have been implicated for EV isolation from cell culture and various tissue fluids on the basis of the immunoaffinity principle, as well as systems. However, some issues are yet to be removed; for instance, the inputted sample shows great possibility to block channels and the efficacy of isolation of EVs is extremely slow, consequently, decreasing their diagnostic potential, 38 and overcome some of the challenges involving in EVs detection, such as the problem of the small size and lacking in distinct biomarkers, which contributing to get a comprehensive understanding function of their contents (eg protein, RNA and lipid).
Several qualitative and quantitative analysis techniques are currently available (Table 3 ). For instance, transmission electron microscopy (TEM) could be combined with immunogold staining to represent structural details and delineate the subpopulations of EVs. 42 A study indicates that cryo-electron microscopy might be more suitable for depicting the morphology of EVs as its no fixation or staining. 43 The size, morphology and intactness of EVs also could be determined by scanning electron microscopy (SEM) and atomic force microscopy (AFM). 44 Measuring the size and number distribution of single EVs can be made by dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA). 45 Both the conventional flow cytometry and novel fluorescence-based flow cytometry could be promising tools to qualitatively and quantitatively analyse the EVs. 46 Western blot, enzyme-linked immunosorbent assay (ELISA) and EVs arrays are used to present purity and enrichment. Micronuclear magnetic resonance [μNMR] system and a photosensitizer-bead detection system (ExoScreen) are other sensitive qualitative and quantitative approaches. [47] [48] [49] As mentioned above ( Table 2) 
| G ENER AL FUN C TI ON S OF E VS IN MALIG NAN CIE S
Bioactive molecules of EVs secreted by both cancer cells and tumour-associated cells provide the essential signals for favouring tumour growth via remodelling the architectures in tumour microenvironments and forming pre-metastatic niches. Different mechanisms of EVs-mediated tumour proliferation and progression will be discussed in the following sections ( Figure 3 ).
| PROMOTION OF ANG IOG ENE S IS
Tumour progression is a dynamic and multistep process requiring continuous nutrient and oxygen supplied by sufficient blood conducts, while also serving to remove waste materials. The advent of cancer stem cells (CSCs) has provided a novel mechanism for the development and progression of the tumour via differentiating into endothelial cells to contribute to the angiogenesis. 50, 51 In addition, a research indicates, for example, that miRNAs, secreted from exosomes, regulate transcription, proliferation, metabolic processing and mRNAs encode vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), angiopoietin1, Ephrin A3, matrix metalloproteinase-2 (MMP-2), and MMP-9 and growth factors in contrast to CD105-negative CSCs. 19 
| EPITHELIAL-TO -ME S EN CHYMAL TR AN S ITI ON
Epithelial-to-mesenchymal transition (EMT) is a developmentally vital reversible process of which fully differentiated cells lose their epithelial features (eg E-cadherin, β-catenin and plakoglobin), acquiring a migratory mesenchymal phenotype (eg N-cadherin and vimentin). EMT also contributes to the metastatic potential of tumours. 52 Exosome mediates that growth in migration and invasion by the way of EMT has been observed in many other studies. [53] [54] [55] Urothelial cells exhibit the EMT after exposing to tumour-derived exosomes. 56 
| FORMATI ON OF PRE-ME TA S TATI C NICHE S
Primary tumours can release some biological factors that migrate to preferred metastatic regions and dynamically remodel these sites before spreading to a distant organ, which means that form predetermined metastatic microenvironments, also referred to as pre-metastatic niches. 57 In general, exosomes display the characteristics of organ tropism, and the process of the construction of pre-metastatic niche involves with initial tumour-derived exosomes releasing into the circulation system and then escaping from the vascular beds to migrate to distant secondary organ. 58, 59 During the process, the crucial initial step is how vascular leaking exosomes can target organ tissues; nowadays, it is induced by complicated processes involved combination of stromal cells and released cancer cell-derived exosomes resulting in reprogramming of these cells [60] [61] [62] [63] and activation of several vital signalling pathways, 64, 65 which alter the local chemokine repertoire of the tumour microenvironment (TME) and remodel the components of the extracellular matrix (ECM) in turns. 61 marrow-derived cells and exosomes in the primary phase of pre-metastatic niche that can stimulate the mobilization of these cells into the circulatory system circulation and disseminate to distant sites, sequentially generate a local pro-inflammatory focus with pro-tumorigenic immunosuppression. [60] [61] [62] 
| MODUL ATION OF THE TUMOUR MICROENVIRONMENT
Accumulating evidence support tumour progression is the consequence of communication between tumour cells and cells within the tumour microenvironment via paracrine or autocrine, such as adipocytes, fibroblasts, immune cells and cells of the vascular. It has been shown that tumour cells have a higher propensity to secrete larger quantity of exosome 67, 68 ; for instance, cancer-associated fibroblasts (CAFs) support tumour cells in proliferation, delaying senescence and resisting against drugs, which induced by exosome-secreted miR-9 and the human telomerase reverse transcriptase (hTERT). 69, 70 Activation of signalling pathways by exosomes is one of the way to modulate the tumour microenvironment, such as irritation of the TGF-β/Smad pathway by transferring TGF-β to human umbilical cord-derived mesenchymal cells (hucMSCs), subsequently differentiating into CAFs. 71 Moreover, recent research shows that transferring TGF-β also contributes fibroblasts converse to myofibroblasts, which could secrete insulin-like growth factor 1 (IGF-1), activin A and VEGF to induce tumour progression. 72 The irritation of another signalling pathway by exosomes in the bidirectional crosstalk between cancer cells and normal stromal cells, such as nuclear factor kappa B (NF-κB) and epidermal growth factor receptor (EGFR) signalling, also plays vital roles in the proliferation and migration of tumour. Endothelial cells show enhanced cell motility and tube formation ability after re-educated by tumour-derived exosomes 73 ; moreover, RNA secreted from EVs develops hepatocyte growth factor synthesis through the activation of ERK1/2 and AKT signalling pathways. 74 It is widely believed that tumour-derived EVs impose significant effects in mediating communication between immune and cancer cells of renal cell cancer (RCC), 75 such as immune evasion of tumours. 76, 77 MiR-222-3p induces polarization of tumour-associated macrophages by the activation of SOCS3/ STAT3 pathway to facilitate tumourigenesis and cancer progression. 78 Additionally, Rab27a supports exosome could modify the tumour microenvironment via advancing recruitment and differentiation of bone marrow-derived neutrophils to cancer cells. 79 Furthermore, a few studies suggest that tumour-derived EVs facilitate cancer progression by attenuating immune and more specific EVs could diminish the cytotoxicity of natural killer cells and T cell in immunoreaction. [80] [81] [82] Tumour-derived EVs also could influence the cancer cells themselves via autocrine to irritate the invasion and migration, and reduce adhesion abilities as well via enhancing MMP-9 or chemokine receptor type 4 (CXCR4). 74 
| MANAG EMENT OF UROLOG I C MALIG NAN CIE S
| K IDNE Y C AN CER (RENAL CELL C AN CER )
Renal cell cancers (RCCs) represent 2%-3% of all cancers. 83, 84 Many kidney cancers remain asymptomatic until the late disease stages with 50% of patients are detected incidentally by non-invasive imaging investigating, and approximately 30% of patients with metastasis in the primary time of diagnosis. 85, 86 The utility of urinary EVs could be recognized as potential diagnostic and prognostic markers in RCCs ( Table 4 ). 87 Proteomic analysis of urinary EVs differs from the patients and healthy groups with showing an RCC-specific signature of the effectiveness of proteins. 58, 88 Another proteins, for instance, podocalyxin (PODXL), WNT signalling pathway inhibitor 4 (DKK4), ceruloplasmin, carbonic anhydrase IX (CAIX) and MMP-9, were validated by using immunoblotting method. 89 In addition, among RCC patients, the mRNA levels of glutathione S-transferase alpha 1 (GSTA1),
CCAAT enhancer binding protein alpha (CEBPA) and PCBD1 in EVs decrease compared with healthy groups. 90 Moreover, a report demonstrates that the lipids within urinary EV show difference between RCC patients and healthy groups. 91 Based on microRNA expression screening, the cluster of miRNAs including miR-449a, miR-126-3p, miR-486-5p and miR-34b-5p could differentiate clear cell RCCs from benign subjects 92 and could be recognized as potential diagnostic and prognostic markers. 58, 93, 94 Serum-derived EVs have also been recognized as prominently diagnostic and prognostic tools for clear cell RCCs. 93, 94 Recently, azurocidin as a permeabilizer for vascular endothelial cells has been isolated from serum-free medium within incubating clear cell RCC tissues samples. 95 Renal cell cancers generate EVs that could educate endothelial 95 and immune cells, 96 with promoting angiogenesis and immunosuppressive activity, respectively. As for immune systems, increasing evidence shows that tumour-derived EVs result in immune evasion of tumours partly via the activation of caspase pathway to trigger apoptosis in T lymphocytes. 97 In addition, both EVs-derived antigens and Hsp70 can inhabit the immunoreaction though induction tumour growth factors of and pro-inflammatory cytokines similarly. 98, 99 Moreover, EVs also can be applied for cancer immunotherapy, mainly due to promoting cytotoxic effects and proliferation of T cells via releasing interferons. 100 What is more, CD105 + stem cells of RCC release EVs that promote and trigger the formation of a pre-metastatic niche by upregulating MMP2 and VEGF 58, 102 ; although sunitinib is a first-line targeted regimen for metastatic RCCs, 103 been confirmed that regulated by lncARSR by promoting MET and AXL expression in RCC cells. 104, 105 Therefore, all those support that EV-based targets display a promising potency for the development of novel cancer therapies.
EVs also can be served as a vaccine for RCCs. A report reveals that RCCs derived from EVs could increase immunogenicity by proliferating T cells and releasing interferons subsequently 100 ; the effectiveness of vaccines when dendritic cells (DCs) load with EVs is higher rather than whole tumour lysate. 98 
| THE B L ADDER C AN CER
Bladder cancer (BCa) is the seventh most commonly diagnosed cancer in the male population worldwide, and the diagnosis for BCa is usually on the basis of cytology, urinalysis and cystoscopy. Cytology is a highly specific test, but low in the sensitivity for the diagnosis of BCa. 106 Cystoscopy is the gold standard to diagnose the BCa, while this method is expensive and invasive, even for flexible cystoscopy, and the risk of developing urinary infections is up to 10% 107 ;
non-invasive and reliable biomarkers are therefore required in the future. Given that, urine is an excellently suitable fluid for biomarkers discovery in BCa. The biomarkers (mainly including proteins, mRNA, lncRNA and miRNA) within EVs isolated from BCa were investigated by different research groups, which could be promising molecules to identify the BCa and predict the progression of the BCa (Table 5 ). Based on proteomic analysis of urinary EVs, several studies have been identified cargoes of possible biomarkers for BC patient, but not in healthy volunteers. 108, 109 Among them, research shows that the levels of tumour-associated calcium-signal transducer 2 (TACSTD2) are correlative with BCa, compared with high-grade BCa.
The author identified seven proteins differentially expressed in the low-risk group (Table 5 ). 109 Proteome profiling of urinary exosomes indicates H2B1K and alpha 1-antitrypsin as prognostic and diagnostic biomarkers for urothelial bladder cancer, which could be verified in immunohistochemistry (IHC). 110 Additionally, HEXB, S100A4 and SND1 significantly identified in EV derived from the MIBC cell line also are upregulating in urinary EV from MIBC patients when vs to normal groups. 111 There are other proteins could be recognized as potential diagnostic and prognostic markers for BCa. [112] [113] [114] [115] Using a whole transcriptome array, a study reports the potential application of mRNAs in urinary EVs for diagnoses, such as LASS2 and GALT1
involving progression with only in BCa patients, and ARHGEF39 and FOXO3 while only expressing in healthy controls to suppress the tumour. 116 In addition, based on the microarray analysis of miRNA, great studies pay their attention on the roles of diagnostic and prognostic. [117] [118] [119] [120] [121] Interestingly, research shows that several microRNAs from urinary EVs significantly upregulate in BCa, but not in plasma from same patients, which suggests that different biofluids may harbour different molecules. 122 Furthermore, to unravel the roles of lncRNA in BCa, recent researches show that lncRNAs, such as HOX-AS-2, HOTAIR, ANRIL and lnc-RoR, are enriched in BCs cancer cell line EVs as well as urinary EVs from high-grade BCa patients, demonstrating that ln-cRNAs have potential as biomarkers for BCa. 123 Additionally, recent reports demonstrate that the CD63 + urinary EVs could be a biomarker for the detection of BCa. 114, 124 EVs derived from BCa cell line also influence local regions microenvironments or distant cells by transferring their content, as result of facilitating proliferation, angiogenesis, invasion, and migration and the inhibition of apoptosis 56, 112, 125 ; for example, EGF-like repeat and discoidin I-like domain-containing protein 3 (EDIL-3) from invasive BCa cell lines could stimulate the migration and angiogenesis of urothelial and endothelial cells. 112 Periostin, another factor from invasive BCa cell lines, could contribute low-grade BCa cancer cells to gain the aggressiveness within via activating ERK oncogenic pathway. 115 Urothelial cells exposed to EVs from cancer cell lines or patient specimen show the phenomena of EMT. 56 Similarly, lncRNA-UCA1, which may be play an important role in causing intratumoural hypoxia, could irritate tumour progression via the EMT as well. 126 However, exosomes also can discard tumour-suppressive miRNAs contributed to BCa progression, such as miR-23b and miR-921, 121 all those could provide underlying targets for the future therapies for the BCa. Recently, a report demonstrates the effectiveness of EVs as a vector to carry siRNAs in BCa; therefore, in the future, EVs have the potential functions to stably deliver substantial therapeutic cargoes including miR-NAs and siRNAs, to anchor organs with the development of tissue engineering technology. 127 
| PROS TATE C AN CER
Prostate cancer (PCa) is the second most commonly diagnosed cancer in men, accounting for 15% of all cancers diagnosed. 128 Although PSA testing contributes to identify and manage PCa in the early phase, it still has some limitations, for example, the specificity of discrimination of benign prostate diseases, such as acute prostatitis and benign hyperplasia. 129 Thus, the more specific and ideal substrate (eg urine, prostatic plasmas and blood samples) for PCa are urgently developed rather than invasive prostate biopsies. 130 Some studies have presented the usefulness of urinary EVs as diagnostic factors (Table 6 ). [131] [132] [133] [134] EV-involved transmembrane proteins CD63 and CD9 are sufficient in urine from PCa. 135 Integrin α3, δ-Catenin, integrin β1 and FABP5 proteins are identified in urinary EVs of PC patients with the significantly increased levels of PCa patients during the process of the investigation of the proteomic cargo of urinary PC-derived EV. [136] [137] [138] [139] Moreover, on the basis of the mass spectrometry proteome analysis, thousands of proteins encapsulated on and within vesicles are identified as biomarker candidates from urinary EVs or cell lines of PCa, [139] [140] [141] [142] [143] [144] [145] [146] whereas the value as biomarkers is still controversial, and several types of research regenerate the previous biomarkers by the using targeted proteomics and immuno-assays. 134 Based on a proximity ligation assay, PC-derived EVs in blood has also shown to contain proteins specific to PCa, such as phosphatase 151 Donovan et al 152 Hendriks et al 153 Motamedinia et al 154 Royo et al 155 (Continues) sequencing reveals the potential values for miRNA served as diagnostic and prognostic biomarkers for PCa within serum or plasma EVs, 41, 131, 132, [158] [159] [160] [161] [162] such as miR-141 and miR-375 in serum, have been correlated with metastatic PCa. 159, 163 Another study indicates that exosomal miR-1290 and miR-375 could be as prognostic markers in castration-resistant prostate cancer (CRPC). 164 In recent, several research works demonstrate that the lipids including diacylglycerol and triacylglycerol are differentially enriched in PCa rather than healthy groups. 165, 166 Glycomic and metabolomic profiling of urinary EV reveal several small molecule metabolites could be novel biomarkers to predict the development of PCa, for example levels of N-linked glycans, glucuronate, adenosine, d-ribose-5-phosphate and isobutyryl-l-carnitine. 167, 168 The intercellular crosstalk through EVs could stimulate tumour progression. Several proteins presenting on and in EVs from PCa cell lines are recognized as significant meditators for the biological communication between cancer cells and tumour microenvironment or surrounding cell, including cytokine CX3CL1, MMPs and transforming growth factor B, play significant roles in the proliferation and differentiation of fibroblasts. 169, 170 In addition, integrins ITGA3 and ITGB1 can affect invasion and migration of normal prostate epithelial cells. 138 Several studies suggest that complicate intercellular interactions between cancer cells, osteoclasts and osteoblasts contribute to bone metastasis. 171, 172 It is the first protein that has been reported in the EVs originated from human hormone-refractory PCa cells to facilitate mouse pre-osteoblast differentiation. 171 response. 174, 175 PCa-derived EVs also involve drug resistance. ABCB1, ABCB4, PABPC4 and SH3GL1 are much more sufficient in EVs from docetaxel-resistant prostate cancer cell lines and potentially higher in serum EVs in men with docetaxel-resistant PCa. 148 AR-V7 is correlated with resistance to enzalutamide and abiraterone in metastatic CRPC patients, which could be a biomarker to predict the CRPC. 176, 177 Finally, EVs-derived PCs can be used as vaccine vesicles that present prostate-associated antigens such as PSA and PAP on their membrane to exert an anti-tumour immune response. 98, 178, 179 and therapeutics owing to their enormous potencies in several aspects, as described below (Figure 4 ). 19 bilayer-membrane structure of EVs. 185 Third, autologous EVs show lower immunogenicity and toxicity than other conventional drug-delivery platforms. 186 Furthermore, EVs possessing specific surface proteins (eg integrins) could bear intrinsic targeting properties that are able to interact with target cells or organs. 187 Although EVs have many advantages as described above, this enormous promise therapeutic delivery tool requires further study for clinical applications.
| D ISCUSS I ON
| ROLE S IN D IAG NOS TI C AND PREDIC TIVE B IOMARKER S
These include the identification of the optimal EV donor cell type, large-scale EVs isolation, preservation of EV structural integrity during drug loading, scalable manufacture and storage. A further challenge remains improving methods to shift in vivo biodistribution of EVs from non-specific sites towards accumulation in desired tissues. Although considerable efforts by engineering EVs to present cell type-specific ligands have been made in guaranteeing rich accumulation in target tissues, one of the major obstacles remains low delivery efficacy. The elucidation to these questions will enhance rationality and reliability to irritate the utility of EV-involving molecular cargoes as cancer diagnostics in the clinical practices. are yet unexplored. With the increasing knowledge of their roles and development of the next-generation sequencing, mass spectrometry-based metabolomics and proteomics, we are enthusiastically sure that EVs will contribute to play clinical applications for urological cancer treatment and management in the near future.
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